Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension (2015)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1093/eurheartj/eht549
- Subjects: EVENTO ADVERSOS A MEDICAMENTOS; FÁRMACOS (SISTEMA CARDIOVASCULAR); HIPERCOLESTEROLEMIA (TERAPIA)
- Language: Inglês
- Imprenta:
- Source:
- Título: European heart journal
- ISSN: 0195-668X
- Volume/Número/Paginação/Ano: v. 36, n. 9, p. 566-575, 2015
- Este artigo possui versão em acesso aberto
- URL de acesso aberto
- PDF de acesso aberto
- Versão do Documento: Versão publicada (Published version)
-
Status: Artigo aberto em periódico híbrido (Hybrid Open Access) -
ABNT
SANTOS, Raul D. et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. European heart journal, v. 36, n. 9, p. 566-575, 2015Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/eht549. Acesso em: 13 mar. 2026. -
APA
Santos, R. D., Duell, P. B., East, C., Guyton, J. R., Moriarty, P. M., Chin, W., & Mittleman, R. S. (2015). Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. European heart journal, 36( 9), 566-575. doi:10.1093/eurheartj/eht549 -
NLM
Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension [Internet]. European heart journal. 2015 ; 36( 9): 566-575.[citado 2026 mar. 13 ] Available from: https://doi.org/10.1093/eurheartj/eht549 -
Vancouver
Santos RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension [Internet]. European heart journal. 2015 ; 36( 9): 566-575.[citado 2026 mar. 13 ] Available from: https://doi.org/10.1093/eurheartj/eht549 - Familial hypercholesterolaemia: PCSK9 inhibitors are coming [comentário]
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
- Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
- USPSTF recommendation on screening for lipid disorders in children and adolescents. [Carta]
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity
- Relation Between Self-Reported Physical Activity Level, Fitness, and Cardiometabolic Risk
- Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know
- The Role of Statins in Current Guidelines
- Evolocumab in pediatric heterozygous familial hypercholesterolemia
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
